After a quick FDA approval in a subset of endometrial cancer, GSK is back with more data for two Jemperli regimens in hopes of reaching a broader patient population. And AstraZeneca, utilizing a ...
If you are wondering whether GSK is still good value after its strong run, you are not alone. This article will walk through ...
On July 31, GSK released its financial results for the second quarter of 2024, which again beat analysts' expectations by a wide margin. Under Emma Walmsley's leadership, the company is becoming a ...
Recent performance and why GSK stock is back on radar GSK (LSE:GSK) has quietly delivered a strong run this year, with the share price up about 34% year to date and roughly 44% over the past year, ...
(Reuters) – Unilever faces a dilemma after its 50 billion pound ($68 billion) offer for GlaxoSmithKline’s consumer healthcare assets was rejected — should it raise the bid and risk overpaying or seek ...
GSK has outperformed both the healthcare sector and S&P 500 this year, which is notable considering the spectre of high ...
A Reuters report regarding the rejection of Unilever's $68 billion offer for GlaxoSmithKline’s consumer healthcare assets is raising questions, including whether Unilever should raise the bid and risk ...
GSK committed $270 million up front in recent months to gain access to early-stage assets in the class of cancer therapies known as antibody drug conjugates, or ADCs. The deals are part of a broad ...
Shortly after winning a stay on a COVID-19 vaccine patent lawsuit brought by Moderna, Pfizer and its German partner BioNTech are being dragged into another round of mRNA litigation by GSK. GSK on ...
GSK plc (NYSE: GSK) appointed Luke Miels as the CEO Designate of GSK. He will assume full responsibility as CEO and join the Board on January 1, 2026. He joined GSK in 2017 and is currently Chief ...
Clinical trials are an essential component of cancer drug development. GSK is transforming trial design to improve patient experience and research output qualityBy Zeshaan Rasheed, Senior Vice ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback